

THE AMERICAN JOURNAL OF MANAGED CARE®

Publishing Staff

Senior Vice President of Operations
and Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Cindy Spielvogel

Project Director

Christina Doong

Quality Assurance Editor

David Allikas

Associate Editor

Jeanne Linke

Design Director

Charles Lebeda

Associate Publisher

Andrew Colon

Director of Sales

Sara Stewart

National Account Managers

Gabrielle Consola

Michael Costella

Corporate

Chairman and CEO

Mike Hennessy

Vice Chairman

Jack Lepping

President

Tighe Blazier

Chief Financial Officer

Neil Glasser, CPA/CFE

President, Managed Markets

Brian Haug

Executive Vice President
and General Manager

John Maglione

Vice President of Human Resources

Rich Weisman

Vice President, Executive Creative
Director

Jeff Brown

Vice President of Education

David Heckard

Copyright © 2015 by Managed Care
& Healthcare Communications, LLC

February 2015 – Vol. 21, No. 4, Sup.

Economic Evaluation of a Fluocinolone Acetonide Intravitreal Implant for Patients With DME Based on the FAME Study

Table of Contents

Participating Faculty

S62

Report

- Economic Evaluation of a Fluocinolone Acetonide
Intravitreal Implant for Patients With DME
Based on the FAME Study

S63

**Antonio Cutino, BA; Kenneth Green, PhD;
Robyn Kendall, PGDip, BSc; Peter T. Moore, MSc;
and Christopher Zachary, MBA**



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ A546

Economic Evaluation of a Fluocinolone Acetonide Intravitreal Implant for Patients With DME Based on the FAME Study

This supplement was sponsored by **Alimera Sciences**.

...

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Economic Evaluation of a Fluocinolone Acetonide Intravitreal Implant for Patients With DME Based on the FAME Study

This supplement to *The American Journal of Managed Care* describes an economic evaluation of a fluocinolone acetonide (FAc) intravitreal implant for patients with diabetic macular edema (DME). The results show that from both a healthcare and societal perspective, the FAc implant is a cost-effective treatment for patients with DME who have received a previous course of a corticosteroid with no clinically significant rise in intraocular pressure.

■ Faculty

Antonio Cutino, BA

Vice President
Medical Affairs
Alimera Sciences
Alpharetta, Georgia

Peter T. Moore, MSc

Lead Health Economist
ICON Health Economics and
Epidemiology
Sydney, Australia

Kenneth Green, PhD

Chief Scientific Officer
Alimera Sciences
Alpharetta, Georgia

Christopher Zachary, MBA

Vice President
US Managed Markets
Alimera Sciences
Alpharetta, Georgia

Robyn Kendall, PGDip, BSc

Health Economist
ICON Commercialization and
Outcomes
Vancouver, BC, Canada

■ Faculty Disclosures

These faculty report relationships with the following organizations:

Antonio Cutino, BA

Employment and stock ownership:
Alimera Sciences

Kenneth Green, PhD

Employment and stock ownership:
Alimera Sciences

Peter T. Moore, MSc

Consultant and receipt of payment for involvement in preparation of manuscript:
Alimera Sciences

Christopher Zachary, MBA

Employment and stock ownership:
Alimera Sciences

Robyn Kendall, PGDip, BSc, reports no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

■ SUPPLEMENT POLICY STATEMENT ■

Standards for Supplements to *The American Journal of Managed Care*

All supplements to *The American Journal of Managed Care* are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All *Journal* supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to *The American Journal of Managed Care* will:

- I. Be reviewed by at least one independent expert from a recognized academic medical institution.
- II. Disclose the source of funding in at least one prominent place.
- III. Disclose any existence of financial interests of supplement contributors to the funding organization.
- IV. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication.
- V. Be up-to-date, reflecting the current (as of date of publication) standard of care.
- VI. Be visually distinct from *The American Journal of Managed Care*.
- VII. Publish information that is substantially different in form and content from that of the accompanying edition of *The American Journal of Managed Care*.
- VIII. Prohibit excessive remuneration for contributors and reviewers.
- IX. Carry no advertising.

Publisher's Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of *The American Journal of Managed Care*. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.